We found that patients with elevated tumor PD-L2 levels had favorable 5-year survival outcomes in advanced stage colon carcinoma compared with patients with low tumor PD-L2 expression, which is consistent with the results from The Cancer Genome Atlas (TCGA)20, especially in patients who received chemotherapy. This evidence concerns the gene PDCD1LG2 and colon carcinoma.